0001834664-23-000002.txt : 20230602 0001834664-23-000002.hdr.sgml : 20230602 20230602103208 ACCESSION NUMBER: 0001834664-23-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230602 DATE AS OF CHANGE: 20230602 EFFECTIVENESS DATE: 20230602 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SURGE Therapeutics, Inc. CENTRAL INDEX KEY: 0001834664 IRS NUMBER: 300961988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-483195 FILM NUMBER: 23987101 BUSINESS ADDRESS: STREET 1: ONE BROADWAY, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-909-8181 MAIL ADDRESS: STREET 1: ONE BROADWAY, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: STIMIT Corp DATE OF NAME CHANGE: 20201202 D 1 primary_doc.xml X0708 D LIVE 0001834664 SURGE Therapeutics, Inc. ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA MASSACHUSETTS 02142 617-909-8181 DELAWARE STIMIT Corp Corporation true Michael S. Goldberg c/o SURGE Therapeutics, Inc. One Broadway, 14th Floor Cambridge MA MASSACHUSETTS 02142 Executive Officer Director Gary Goldberg c/o SURGE Therapeutics, Inc. One Broadway, 14th Floor Cambridge MA MASSACHUSETTS 02142 Director Ali Farahanchi c/o SURGE Therapeutics, Inc. One Broadway, 14th Floor Cambridge MA MASSACHUSETTS 02142 Director Jason Coloma c/o SURGE Therapeutics, Inc. One Broadway, 14th Floor Cambridge MA MASSACHUSETTS 02142 Director Kouki Harasaki c/o SURGE Therapeutics, Inc. One Broadway, 14th Floor Cambridge MA MASSACHUSETTS 02142 Director Chuck Carignan c/o SURGE Therapeutics, Inc. One Broadway, 14th Floor Cambridge MA MASSACHUSETTS 02142 Executive Officer Antonio Gualberto c/o SURGE Therapeutics, Inc. One Broadway, 14th Floor Cambridge MA MASSACHUSETTS 02142 Executive Officer Biotechnology Decline to Disclose 06b false 2023-05-19 false true false 0 49999998 32003969 17996029 false 22 0 0 4444000 Estimate for next three years. false SURGE Therapeutics, Inc. /s/ Michael S. Goldberg Michael S. Goldberg President and Chief Executive Officer 2023-05-24